ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2207

Knowledge, Awareness, and Attitudes Regarding Inflammatory Back Pain Among Non-Rheumatology Physicians in the United States

William Odell1, Swetha Ann Alexander2, Nicolas Page3, Narinder Maheshwari4 and Abhijeet Danve5, 1Yale University, Wethersfield, CT, 2University of Utah Health, Salt Lake City, UT, 3Yale University, New Haven, CT, 4UCONN Health, Farmington, CT, 5Yale University School of Medicine, Glastonbury, CT

Meeting: ACR Convergence 2023

Keywords: Back pain, Education, spondyloarthritis, Surveys

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2195–2226) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: SpA

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Inflammatory back pain (IBP) is the defining feature of axial spondyloarthritis (axSpA). However, it may be difficult for non-rheumatology physicians (non-rheums) to distinguish between mechanical and inflammatory back pain (IBP) thus contributing to delayed and missed diagnosis. This study aims to systematically survey non-rheums in the US to gain insights into their knowledge, awareness, and attitudes towards IBP. The objective is to identify barriers for timely referral and opportunities for intervention.

Methods: An online survey questionnaire was developed and refined using input from previous smaller regional studies, methodologies, and pilot testing. The survey included demographic information, practice patterns, and questions about the knowledge and approach toward IBP and axSpA. The survey was distributed to non-rheums taking care of chronic back pain (CBP) patients, namely Family/Internal Medicine, Spine Surgery/Orthopedics, Pain Medicine, and Physical Medicine/Physiatry/Rehabilitation across the US using third-party vendors. The survey was also sent to rheumatologists (rheums), who served as the comparator group. Descriptive statistics was used to summarize the results.

Results: Of 3136 physicians who received the survey, 750 completed it (response rate 24%). Table 1 presents information regarding physician specialty, demographics, and practice details. Physicians with variable years of practice experience were included (40% < 5-15 years, 40% 15-30 years, and 10% > 30 years). Respondents reported CBP as a common symptom among the patients; 72% of physicians reported CBP in 15% of their patients and 44% in 30% of patients. Seventy percent of non-rheums reported that 15 to 50% of their CBP patients have onset before age 50 years. About 75% of non-rheums are either moderately or very familiar with the term IBP; an additional 15% are somewhat familiar. Only 21% of non-rheums could identify all 8 IBP items, but 87% could recognize more than 4 of 8 IBP items (Figure 1). Among rheums, 69 % could recognize all eight features, and 27% could recognize 7 of 8 features. About 60% of non-rheums do not routinely assess CBP patients for IBP; 14% rarely/ never assess, and 45% assess for IBP sometimes (Figure 2). In contrast, 99% of rheums are routinely assessed for IBP. Data about the IBP and response rates remained consistent across the non-rheums surveyed.

Conclusion: In this large nationwide survey study involving physicians from different specialties who manage CBP, we found that non-rheums are familiar with the term IBP, and the majority may have optimal knowledge about the IBP items, but fewer actually assess the CBP patients for the presence of IBP in routine practice. The use of computerized Clinical Decision Support Systems (CDSS) and improved education regarding the true prevalence of axSpA may help to wind down this barrier.

Supporting image 1

Table 1: Respondent demographics and practice details.

Supporting image 2

Figure 1: Percentages of rheumatology (a) and non-rheumatology (b) respondents who selected correct answer choices (shown in Figure) describing inflammatory back pain out of 16 choices, with 8 being highest score possible.

Supporting image 3

Figure 2: Percentages of rheumatology (a) and non-rheumatology (b) respondents who consider or assess for inflammatory back pain in practice for patients with chronic back pain


Disclosures: W. Odell: None; S. Alexander: None; N. Page: None; N. Maheshwari: Moderna, 12, Part of clinical trial by Moderna; A. Danve: Abbvie, 2, Amgen, 2, Janssen, 2, Lilly, 5, Medscape, 6, Novartis, 2, 5, Spondylitis Association of America, 5, Spondyloarthritis Research and Treatment Network, 5, UCB, 1.

To cite this abstract in AMA style:

Odell W, Alexander S, Page N, Maheshwari N, Danve A. Knowledge, Awareness, and Attitudes Regarding Inflammatory Back Pain Among Non-Rheumatology Physicians in the United States [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/knowledge-awareness-and-attitudes-regarding-inflammatory-back-pain-among-non-rheumatology-physicians-in-the-united-states/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/knowledge-awareness-and-attitudes-regarding-inflammatory-back-pain-among-non-rheumatology-physicians-in-the-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology